{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:58:09Z","timestamp":1792065489752,"version":"4.4.0"},"reference-count":30,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Recurrent glioblastoma has a poor prognosis and no universally accepted standard of care. Regorafenib has been investigated in this setting, but its use may be limited by treatment-related toxicity. This study evaluated the feasibility, safety, and clinical outcomes of reduced-dose regorafenib in patients with recurrent IDH-wildtype glioblastoma. Methods: We retrospectively analyzed 21 patients with recurrent IDH-wildtype glioblastoma (WHO 2021) treated at a single center after progression according to the Stupp protocol. Regorafenib was started at 80 mg\/day on the standard 3-weeks-on\/1-week-off schedule. We assessed overall survival from diagnosis (OS1) and from first progression (OS2), progression-free survival from diagnosis (PFS1) and from first progression (PFS2), treatment exposure, dose modifications, and treatment-related adverse events (CTCAE v5.0). Results: Median PFS2 was 5 months (95% CI, 3\u20138), median OS2 was 6 months (95% CI, 5\u201310), and median OS1 was 21 months (95% CI, 15\u201327). No grade \u2265 3 adverse events occurred, and no patient discontinued treatment permanently because of toxicity. Conclusions: In this retrospective single-center cohort, reduced-dose regorafenib was feasible and well tolerated in selected patients. These descriptive, hypothesis-generating findings warrant prospective studies to define the role of individualized regorafenib dosing in recurrent glioblastoma.<\/jats:p>","DOI":"10.3390\/cancers18152522","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T08:08:02Z","timestamp":1786003682000},"page":"2522","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced-Dose Regorafenib for Recurrent Glioblastoma: A Safety and Outcome Analysis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6008-7579","authenticated-orcid":false,"given":"Massimiliano","family":"Rizzaro","sequence":"first","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"},{"name":"Neurosurgery Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-036X","authenticated-orcid":false,"given":"Claudia","family":"Fanizzi","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-3675","authenticated-orcid":false,"given":"Giorgio","family":"Fiore","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4118-9009","authenticated-orcid":false,"given":"Luigi","family":"Remore","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Neuroradiology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9102-7547","authenticated-orcid":false,"given":"Elena","family":"Scagliotti","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"given":"Giovanni","family":"Pratelli","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"},{"name":"Neurosurgery Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7393-892X","authenticated-orcid":false,"given":"Stefano","family":"Borsa","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-9146","authenticated-orcid":false,"given":"Stefania","family":"Navone","sequence":"additional","affiliation":[{"name":"Center for Aerospace Medicine and Advanced Therapies\u2014CeMATA\u2014Laboratory of Experimental Neurosurgery and Cell Therapy, Unit of Neurosurgery, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Bertorelli","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"given":"Luca","family":"Sironi","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Roda","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-7000","authenticated-orcid":false,"given":"Giovanni","family":"Marfia","sequence":"additional","affiliation":[{"name":"Center for Aerospace Medicine and Advanced Therapies\u2014CeMATA\u2014Laboratory of Experimental Neurosurgery and Cell Therapy, Unit of Neurosurgery, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"given":"Manuela","family":"Caroli","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]},{"given":"Marco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy"},{"name":"Neurosurgery Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"De Vleeschouwer, S. (2017). Epidemiology and Outcome of Glioblastoma. Glioblastoma, Exon Publications.","DOI":"10.15586\/codon.glioblastoma.2017"},{"key":"ref_2","first-page":"e8195","article-title":"Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population","volume":"12","author":"Grech","year":"2020","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and Molecular Prognostic Review of Glioblastoma","volume":"23","author":"Thakkar","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jain, K.K. (2018). A Critical Overview of Targeted Therapies for Glioblastoma. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00419"},{"key":"ref_5","first-page":"185","article-title":"Immunotherapy in Glioblastoma: An Overview of Current Status","volume":"17","author":"Sarfraz","year":"2025","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4143\/crt.2014.259","article-title":"Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge","volume":"48","author":"Navarria","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Vaz-Salgado, M.A., Villamayor, M., Albarr\u00e1n, V., Al\u00eda, V., Sotoca, P., Chamorro, J., Rosero, D., Barrill, A.M., Mart\u00edn, M., and Fernandez, E. (2023). Recurrent Glioblastoma: A Review of the Treatment Options. Cancers, 15.","DOI":"10.3390\/cancers15174279"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Chang, C., Chavarro, V.S., Gerstl, J.V.E., Blitz, S.E., Spanehl, L., Dubinski, D., Valdes, P.A., Tran, L.N., Gupta, S., and Esposito, L. (2024). Recurrent Glioblastoma\u2014Molecular Underpinnings and Evolving Treatment Paradigms. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126733"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e142227","DOI":"10.3897\/folmed.67.e142227","article-title":"Prognostic factors and survival of recurrent glioblastoma: A systematic review","volume":"67","author":"Aman","year":"2025","journal-title":"Folia Medica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and Bevacizumab in Progressive Glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.23736\/S0390-5616.25.06421-5","article-title":"Optimal MGMT promoter methylation cut-off to predict better survival in glioblastoma patients undergoing gross-total resection","volume":"70","author":"Fanizzi","year":"2026","journal-title":"J. Neurosurg. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO-25-01137","article-title":"Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II\/III Bayesian Randomized Platform Trial","volume":"44","author":"Wen","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/erm.2024.8","article-title":"Regorafenib and glioblastoma: A literature review of preclinical studies, molecular mechanisms and clinical effectiveness","volume":"26","author":"Mongiardi","year":"2024","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","article-title":"Regorafenib","volume":"211","author":"Ettrich","year":"2018","journal-title":"Recent Res. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","article-title":"Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model","volume":"12","author":"Arns","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"CTCAE versi\u00f3n 5.0. Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas","volume":"112","author":"Santana","year":"2021","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102943","DOI":"10.1016\/j.esmoop.2024.102943","article-title":"REGOMA-OSS: A large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma","volume":"9","author":"Caccese","year":"2024","journal-title":"ESMO Open"},{"key":"ref_22","unstructured":"(2012). FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncology, 26, 896."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"(2013). FDA Approves Stivarga for Advanced GIST. Oncol. Times, 35, 12.","DOI":"10.1097\/01.COT.0000428635.32713.a9"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"(2017). Regorafenib Approved for Liver Cancer. Cancer Discov., 7, 660.","DOI":"10.1158\/2159-8290.CD-NB2017-070"},{"key":"ref_25","first-page":"837","article-title":"Prevention and management of adverse events related to regorafenib","volume":"22","author":"Saettini","year":"2013","journal-title":"Support. Care Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand\u2013foot skin reaction: Practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug\u2013drug interactions with tyrosine-kinase inhibitors: A clinical perspective","volume":"15","author":"Mathijssen","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835918818347","article-title":"Clinically relevant drug interactions with multikinase inhibitors: A review","volume":"11","author":"Hussaarts","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11060-022-04155-9","article-title":"Observational real-life study on regorafenib in recurrent glioblastoma: Does dose reduction reduce toxicity while maintaining the efficacy?","volume":"160","author":"Bruno","year":"2022","journal-title":"J. Neuro-Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Signorelli, C., Basso, M., Calegari, M.A., Anghelone, A., Passardi, A., Gallio, C., Bittoni, A., Lucchetti, J., Angotti, L., and Di Giacomo, E. (2025). Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study. Cancers, 17.","DOI":"10.3390\/cancers17203316"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2522\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:42:48Z","timestamp":1792064568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":30,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152522"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152522","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}